Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


eISSN: 1643-3750

Assessment of fusafungine efficacy and tolerance in upper respiratory infections

Bolesław Samoliński, Janusz Kamiński, Marcin Kargul

Med Sci Monit 1996; 2(5): PI650-656

ID: 500092

Available online: 1996-09-02

Published: 1996-09-02

Assessment of clinical efficacy of fusafungine, a preparation combining properties of antibiotic and antiinflammatory agents, was carried out on a group of 1325 patients with symptoms of acute inflammation of the nasal mucosa, sinuses, pharynx, palatine tonsils and bronchi. Patients were subjected to a seven-day treatment and evaluation. Fusafungine effects on particular symptoms and clinical efficacy were assessed by both patients and their physicians in charge. The study was done as an open multicentre trial. In 35% of patients antiinflammatory nonsteroid drugs were administered; 18% of patients received general antibiotics (50% of those were given in bronchitis). Statistically significant differences in remission were noted in the majority of conditions as early as the first 24 hours (p<0.01). The best results were observed in acute palatine tonsillitis (except for streptococcal pharyngitis) and acute rhinitis and pharyngitis (very good and good results represented by 92% and 93% respectively). In bronchitis and sinusitis the effects were milder (77% and 78% respectively). Sore throat, hoarseness and nasal congestion showed the most effective (over 40%) and quickest (50% symptom reduction at 4 days) remission. The poorest results were observed in remission of cough and rhinorrhoea (less than 35% improvement, 50% symptom reduction as late as at 7 days). In general the best results were noted in 39%, good in 48% and poor in 13% of the patients. A poor response was observed in 4% of cases. Adverse symptoms were reported by 8% of patients and proved to be local.

Keywords: Sinusitis, Pharyngitis, Laryngitis, Bronchitis, antibiotic therapy, fusafungine